Clinical Trial Update: Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab in combination with decitabine for relapsed/refractory or advanced extranodal NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• Decitabine (Decitabine)
• Sintilimab (sintilimab)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Extranodal NK/T-cell Lymphoma | Phase 2 | Status: UNKNOWN